Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Comment by 90guppyon Dec 08, 2020 1:50pm
55 Views
Post# 32059194

RE:VAXIL PRIVATE OFFERING

RE:VAXIL PRIVATE OFFERINGLook Corvax for the genetically modified mice is already made and delivered to USAMRIID, less than a week from now, they will start injecting and result will come out in January. That is all that matters now.  If they cancel the remaining pp portion so be it, less needed dilution anyways. Do they need the money, maybe not anymore, Corvax is already in USARMRIID hands. Extra money would not have made any difference at all. So for me, if its not needed and all bet is on the USAMRIID test, might as well cancel that remaining pp.


Charleyfarley wrote:
Remains open to anyone willing to make a calculated , but , as it stands very uncalculated and full of the danger of Failure or Loss type of investment. hence the Price of .075 cents. There is a commission structure in place which could counteract such Risk . So it will remain Buyer Beware until such time that the company decides to share ongoing developments with shareholders.


<< Previous
Bullboard Posts
Next >>